Vectibix® is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): ...Read More
Presented at ASCO, June 2022
*Defined as wild type in both KRAS and NRAS.1
mCRC = metastatic colorectal cancer
Dr. Fakih is a paid consultant for Amgen.
In collaboration with ReachMD.
*Defined as wild type in both KRAS and
NRAS.1
†OS with updated information based
on events in 82% of patients.1
‡See the guidelines
online at NCCN.org for the full recommendation.
§NCCN makes no
warranties of any kind whatsoever regarding their content, use or application and disclaims any
responsibility for their
applications or use in any way.
CI =
confidence interval; HR = hazard ratio; FOLFOX = fluorouracil, leucovorin, and oxaliplatin; mCRC =
metastatic colorectal cancer;
NCCN = National Comprehensive Cancer
Network; OS = overall survival; PRIME = Panitumumab Randomized Trial in Combination With
Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy;
WT = wild type.
IMPORTANT SAFETY INFORMATION
Please see Vectibix® full Prescribing Information, including Boxed WARNINGBoxed WARNING.
Indication
Vectibix® is indicated for the treatment of patients with wild‑type RAS (defined as wild‑type in both KRAS and NRAS as determined by an FDA‑approved test for this use) metastatic colorectal cancer (mCRC):
Limitation of Use
Vectibix® is not indicated for the treatment of patients with RAS‑mutant mCRC or for whom RAS mutation status is unknown.